Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Tecnoloxía para a monitorización e control de Diabetes

Resultados 113 resultados
LastUpdate Última actualización 10/04/2026 [19:34:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
Resultados 1 a 25 de 113 nextPage  

REAL TIME MANAGEMENT OF DATA RELATING TO PHYSIOLOGICAL CONTROL OF GLUCOSE LEVELS

NºPublicación:  FI3173014T4 09/04/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
FI_3173014_T4

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

INFUSION PUMP WITH MULTI-CGM COMPATIBILITY

NºPublicación:  AU2024350322A1 09/04/2026
Solicitante: 
TANDEM DIABETES CARE INC
AU_2024350322_PA

Resumen de: AU2024350322A1

Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.

SYSTEMS AND METHODS FOR ANALYZING, INTERPRETING, AND ACTING ON CONTINUOUS GLUCOSE MONITORING DATA

NºPublicación:  AU2026202087A1 09/04/2026
Solicitante: 
WELLDOC INC
AU_2026202087_A1

Resumen de: AU2026202087A1

Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self- management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.20 ar a r

APPLICATORS FOR GLUCOSE MONITORS AND METHODS FOR APPLYING GLUCOSE MONITORS

NºPublicación:  EP4719193A1 08/04/2026
Solicitante: 
LAXMI THERAPEUTIC DEVICES INC [US]
EP_1000000_PA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

ZWITTERION SURFACE MODIFICATIONS FOR CONTINUOUS SENSORS

NºPublicación:  EP4721659A2 08/04/2026
Solicitante: 
DEXCOM INC [US]
EP_4721659_A2

Resumen de: EP4721659A2

0001 Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a continuous analyte sensor 34 configured to generate a signal associated with a concentration of an analyte, a reference electrode 30, and a sensing membrane 32 located over the working electrode 38. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.

OPEN LOOP INTELLIGENT DOSING

NºPublicación:  EP4723123A1 08/04/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
EP_4723123_A1

Resumen de: EP4723123A1

Systems, devices, and techniques are disclosed for providing personalized insulin dosage recommendations for a patient. In some aspects, a method includes generating a physiological model for estimating glucose values of the patient based on historical data, the historical data comprising glucose value history and insulin dosage history for a time window during which the patient consumed a plurality of meals. The method also may include estimating, using the physiological model and the historical data, an impact of the plurality of meals on the glucose values of the patient, and receiving a first meal size indication of a first meal for consumption by the patient. The method may also include outputting a first meal bolus insulin dose recommendation based on the impact of the plurality of meals on the glucose values of the patient and the first meal size indication.

Method and apparatus for determining medication dose information

NºPublicación:  AU2026202005A1 02/04/2026
Solicitante: 
ABBOTT DIABETES CARE INC
Abbott Diabetes Care Inc
AU_2026202005_A1

Resumen de: AU2026202005A1

Methods, devices, and kits are provided for determining a recommended insulin dose to be administered to user based upon analyte data determined by an analyte sensor. ar a r

METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR REAL-TIME DETECTION OF SENSITIVITY DECLINE IN ANALYTE SENSORS

NºPublicación:  US20260095261A1 02/04/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
UNIV OF VIRGINIA PATENT FOUNDATION [US]
ABBOTT DIABETES CARE INC,
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
US_20260095261_A1

Resumen de: US20260095261A1

Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.

BIOCOMPATIBLE FILM FOR BIOSENSOR AND GLUCOSE SENSOR

NºPublicación:  WO2026065646A1 02/04/2026
Solicitante: 
OXSYNS TECH CO LTD [CN]
\u6DF1\u5733\u6D25\u5408\u751F\u7269\u6709\u9650\u516C\u53F8
WO_2026065646_A1

Resumen de: WO2026065646A1

Disclosed are a biocompatible film for a biosensor and a glucose sensor. The biocompatible film is prepared by coating a film solution by means of a coating process. The film solution comprises a cofactor-grafted polymer, an organic solvent, and a buffer solution. An end portion of each branch of the cofactor-grafted polymer has a cofactor grafted thereto. The backbone of the cofactor-grafted polymer is one or more of polyurethane, polyvinyl alcohol, a polyvinyl alcohol derivative, polyvinylpyrrolidone, a polyvinylpyrrolidone derivative, polyvinylpyridine, and a polyvinylpyridine derivative. The branches of the cofactor-grafted polymer are one or more of acetic acid, butyric acid, ethyl butyrate, caproic acid, and ethyl hexanoate. The biocompatible film can achieve precise regulation of chemical substance permeability, expand the linear detection range of the biosensor for chemical substances, and provide the cofactors required during chemical substance detection, thereby improving the stability and durability of the biosensor.

Systems and methods for health data visualization and user support tools for continuous glucose monitoring

NºPublicación:  AU2026201970A1 02/04/2026
Solicitante: 
DEXCOM INC
Dexcom, Inc
AU_2026201970_A1

Resumen de: AU2026201970A1

MARKED-UP COPY MARKED-UP COPY Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host. ar a r

SYSTEM AND METHOD FOR ONLINE DOMAIN ADAPTATION OF MODELS FOR HYPOGLYCEMIA PREDICTION IN TYPE 1 DIABETES

NºPublicación:  AU2026201926A1 02/04/2026
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION
University of Virginia Patent Foundation
AU_2026201926_A1

Resumen de: AU2026201926A1

22514182_1 (GHMatters) P118105.AU.1 Embodiments relate to an adaptive glycemia monitoring and forecasting system that includes an event monitor configured to receive blood glucose levels of an individual or information about an activity performed by the individual, and generate an event output. The system includes a control module configured to pull observation data, predictor variables, and population estimated vector of covariate weightings coefficients from a database, and generate updated estimated vector of covariate weightings coefficients for the individual user based on the event output. The updated estimated vector of covariate weightings coefficients are determined by a cross-entropy loss objective function. The updated estimated vector of covariate weightings coefficients are used to predict at least one or more of a predicted hypoglycemia state, a predicted normal glycemia state, or a predicted hyperglycemia state for the individual user. the individual user. ar a r

COMPENSATION METHOD AND DEVICE FOR CONTINUOUS GLUCOSE MONITORING APPARAUS

NºPublicación:  WO2026067891A1 02/04/2026
Solicitante: 
JIANGSU YUWELL POCTECH BIOTECHNOLOGY CO LTD [CN]
ZHEJIANG POCTECH CO LTD [CN]
JIANGSU YUEKAI BIOTECHNOLOGY CO LTD [CN]
JIANGSU YUWELL POCTECH BIOTECHNOLOGY CO., LTD,
ZHEJIANG POCTECH CO., LTD,
JIANGSU YUEKAI BIOTECHNOLOGY CO., LTD
WO_2026067891_A1

Resumen de: WO2026067891A1

A compensation method and device for a continuous glucose monitor includes: acquiring a real-time glucose value of a user continuously(S101); determining a user type and a glucose trend type according to the real-time glucose value, where the user type includes at least a first user type and a second user type(S102); determining, based on the real-time glucose value, whether a compensation start condition is satisfied; starting a compensation algorithm if the compensation start condition is satisfied(S103); determining a compensation formula based on the real-time glucose value, the glucose trend type, and the user type(S104); and obtaining, based on the real-time glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied(S105).

RING-STRUCTURED NON-INVASIVE BLOOD GLUCOSE SENSOR, NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICE, AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT METHOD

NºPublicación:  WO2026071284A1 02/04/2026
Solicitante: 
CENTER FOR ADVANCED META MAT [KR]
\uC7AC\uB2E8\uBC95\uC778 \uD30C\uB3D9\uC5D0\uB108\uC9C0 \uADF9\uD55C\uC81C\uC5B4 \uC5F0\uAD6C\uB2E8
WO_2026071284_A1

Resumen de: WO2026071284A1

A ring-structured non-invasive blood glucose sensor according to the present invention comprises: a transmission unit which is provided in a first ring structure, and which generates electromagnetic waves and irradiates same toward the center of the first ring structure; an active element which is provided in a second ring structure that is smaller than the first ring structure and is disposed inside the first ring structure, and which amplifies the electromagnetic waves irradiated by the transmission unit so that the amplified electromagnetic waves are directed toward an object to be inspected disposed inside the second ring structure; a reception unit which is provided to be spaced apart from the transmission unit in the first ring structure, and which receives electromagnetic waves reflected or scattered from the object to be inspected; and a conductor, which is disposed to be adjacent to the first ring structure and the second ring structure, propagates the electromagnetic waves amplified by the active element toward the object to be inspected, by virtue of a space defined by a conductor, and strengthens a resonance phenomenon by strengthening an electromagnetic field within the defined space.

DRUG DELIVERY SYSTEM WITH GRAPHICAL USER INTERFACE

NºPublicación:  US20260091175A1 02/04/2026
Solicitante: 
MEDTRUM TECH INC [CN]
MEDTRUM TECHNOLOGIES INC
US_20260091175_A1

Resumen de: US20260091175A1

The invention discloses a drug delivery system with graphical user interface comprises a detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.

System and method for decision support

NºPublicación:  AU2026201971A1 02/04/2026
Solicitante: 
DEXCOM INC
Dexcom, Inc
AU_2026201971_A1

Resumen de: AU2026201971A1

Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state. ar a r

System and method for artificial pancreas with multi-stage model predictive control

NºPublicación:  AU2026201994A1 02/04/2026
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION
University of Virginia Patent Foundation
AU_2026201994_A1

Resumen de: AU2026201994A1

22510489_1 (GHMatters) P117930.AU.1 Provided are a system and method for an artificial pancreas having multi-stage model predictive control to minimize and/or prevent occurrence of hypoglycemia associated with Type 1 diabetes. The control implements predictive modeling of a probability of glucose uptake associated with exercise based on at least one exercise 5 profile for a subject with Type 1 diabetes. Based on the probability, the control implements an automatic adjustment of basal insulin infusion to counteract a risk of exercise-induced hypoglycemia in advance of the subject engaging in the exercise. The control further implements adjustment of such infusion based on real-time signaling of exercise likely to induce hypoglycemia. Prior to consumption of a meal, the control 10 further implements adjustment of a meal-time bolus so as to account for the effect of delay in glucose uptake resulting from exercise previously engaged in by the subject. Consequently, the control acts to minimize and/or prevent hypoglycemia from occurring both during and immediately after the subject engages in exercise. ar a r

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

NºPublicación:  EP4717171A2 01/04/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
EP_4717171_A2

Resumen de: EP4717171A2

According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.

BLOOD GLUCOSE MEASUREMENT BASED ON RAMAN SPECTROSCOPY

NºPublicación:  EP4716499A1 01/04/2026
Solicitante: 
APOLLON INC [KR]
Apollon Inc
CN_121604922_PA

Resumen de: AU2024280120A1

Blood glucose level measurement includes a light source configured to irradiate light to a subject; a monochrome part configured to separate wavelength components of the light that is reflected and scattered from the subject; a light receiver configured to receive the light transmitted via the monochrome part and to generate electrical signals based on the received light; and a processor configured to extract information on the blood glucose level of the subject based on a frequency shift of the light due to the Raman effect.

Pattern discovery in continuous glucose monitoring data

NºPublicación:  US12588838B1 31/03/2026
Solicitante: 
VERILY LIFE SCIENCES LLC [US]
Verily Life Sciences LLC
US_12588838_B1

Resumen de: US12588838B1

Introduced here are diabetes management platforms able to examine glucose measurements associated with a subject to discover patterns indicative of similar behaviors/circumstances. More specifically, a diabetes management platform can acquire multiple data series generated by a glucose monitoring device that monitors the blood glucose level of an individual over multiple time intervals. The diabetes management platform can then apply a similarity algorithm to produce a distance measure (also referred to as a “similarity measure”) for each data series. For example, the diabetes management platform may, for each data series, perform dynamic time warping to produce a distance measure with respect to each of the other data series. The diabetes management platform can identify patterns indicative of similar behaviors/circumstances based on these distance measures.

SYSTEMS FOR PROVIDING PROFESSIONAL TREATMENT GUIDANCE FOR DIABETES PATIENTS

NºPublicación:  ES3060889T3 30/03/2026
Solicitante: 
TIGAR HEALTH INC
EP_1000000_PA

Resumen de: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

METHOD FOR CONTROLLING BLOOD GLUCOSE AND ARTIFICIAL PANCREAS SYSTEM FOR CARRYING OUT THE METHOD

NºPublicación:  AU2024331938A1 26/03/2026
Solicitante: 
UNIV POLITECNICA DE VALENCIA
UNIVERSITAT POLIT\u00C8CNICA DE VAL\u00C8NCIA
AU_2024331938_A1

Resumen de: WO2025046158A1

The invention relates to a method for controlling glucose in a flexible-structure bihormonal artificial pancreas that manages optional meal and/or exercise alerts by means of coordinated control actions, comprising: measuring a plasma glucose signal; calculating an incremental plasma glucose measurement (y); defining a model for incremental plasma glucose; defining a carbohydrate ingestion as dependent on a carbohydrate content estimated by the patient; defining an expected postprandial incremental plasma glucose y*(s) according to an insulin bolus that has been administered; defining a corrected incremental plasma glucose y̅(s), a corrected insulin infusion ū(s) and a corrected carbohydrate ingestion d̅(s); defining a virtual control action μ(s), divided between regulatory actions μ r and counterregulatory actions μ cr ; and calculating the control actions using a 2-DOF feedback controller with a prefilter having a nominal value F r (s).

SITE TRACKING BASED ON CONNECTIVITY IN INFUSION PUMP SYSTEMS

NºPublicación:  US20260083911A1 26/03/2026
Solicitante: 
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc
US_20260083911_A1

Resumen de: US20260083911A1

Enclosed herein are methods and systems for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, and a smartphone or other multi-purpose consumer electronic device (i.e., remote control device). Communications among these devices can be coordinated to ensure reliable and consistent transmission of medical data.

METHOD OF DETERMINING GLUCOSE CONCENTRATION IN TISSUE, COMPUTER PROGRAM PRODUCT, RADIOMETER AND A SYSTEM THEREFOR

NºPublicación:  AU2024351716A1 26/03/2026
Solicitante: 
MEDISENSONIC SPOLKA AKCYJNA
MEDISENSONIC SPOLKA AKCYJNA
AU_2024351716_PA

Resumen de: AU2024351716A1

A method of non-invasive determination of the blood glucose concentration in the patient's tissue based on a radio noise signal received using an antenna brought close to the patient's skin according to the invention involves use of the radio noise signal is measured using a passive radiometer and additionally the method includes the following steps: a step of obtaining transformation coefficients, a step of measuring the temperature of the tissue surface, a step of measuring the temperatures of the active elements of the receiving chain of the radiometer, a step of measuring the currents consumed by the active elements of the receiving chain of the radiometer, a step of measuring the power of the radio noise signal originating from the tissue, and a step of determining the blood glucose concentration based on the aforementioned values. The invention also relates to a computer program, a radiometer, and a device for determining glucose concentration.

SYSTEMS FOR DETERMINING SIMILARITY OF SEQUENCES OF GLUCOSE VALUES

NºPublicación:  US20260083358A1 26/03/2026
Solicitante: 
DEXCOM INC [US]
Dexcom, Inc
US_20260083358_A1

Resumen de: US20260083358A1

In implementations of systems for determining a similarity of sequences of glucose values, a computing device implements a similarity system to receive input data describing a sequence of user glucose values measured by a continuous glucose monitoring (CGM) system. The similarity system computes similarity scores for a plurality of sequences of glucose values by comparing each glucose values included in the sequence of user glucose values with ever glucose value included in each sequence of the plurality of sequences. A particular sequence of glucose values that is associated with a highest similarity score is identified. The similarity system determines an externality associated with the particular sequence. The similarity system generates an indication of the externality for display in a user interface.

ADJUSTMENT OF MEDICAMENT DELIVERY BY A MEDICAMENT DELIVERY DEVICE BASED ON MENSTRUAL CYCLE PHASE

Nº publicación: US20260083912A1 26/03/2026

Solicitante:

INSULET CORP [US]
INSULET CORPORATION

US_20260083912_A1

Resumen de: US20260083912A1

Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.

traducir